Drug intelligence / Profile preview

ACWYVax

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

ACWYVax is a quadrivalent meningococcal polysaccharide vaccine designed to provide active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W, and Y. It functions by stimulating the body's immune system to produce specific antibodies against the capsular polysaccharides of these bacterial serogroups, thereby conferring protection against infections such as meningitis and sepsis. This vaccine was developed by GlaxoSmithKline and has been evaluated in clinical trials.

Brand names: ACWY Vax

Targets

Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)

Beyond the preview

Go deeper on ACWYVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACWYVax.

Explore the full profile